医学课件PRISM-PLUS糖尿病亚组研究

Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,PRISM-PLUS:Demographics of Patients With Diabetes,Patients WithoutPatients With,DiabetesDiabetes,(n=1208)(n=362),Mean age(y)6266,Prior MI40%47%,Heart failure7%16%,PTCA31%28%,CABG23%24%,PRISM-PLUS:MI/Death Outcomes in Patients With Diabetes,%Patients,9.3%,1.2%,P,=0.004,15.5%,4.7%,P,=0.002,19.2%,11.2%,P,=0.044,Day 7,Day 30,Day 180,5,0,15,10,20,PRISM-PLUS:MI in Patients With Diabetes,%Patients,7.8%,0%,P,0.001,11.4%,1.8%,P,=0.002,13.5%,4.7%,P,=0.008,Day 7,Day 30,Day 180,5,0,15,10,20,PRISM-PLUS:Results in Patients With Diabetes,Conclusion,Tirofiban+heparin therapy resulted in a marked sustained reduction in major cardiac outcomes,particularly recurrent MI,in patients with diabetes presenting with UAP/NQWMI.,